Initial bevacizumab therapy has been associated with improved OS, reinforcing its potential role in GBM treatment.364 Ogremorphin, a GPR68 inhibitor, induces ferroptosis and cytotoxicity in GBM cells with minimal toxicity, highlighting its potential as a therapeutic strategy. The gene discussed is GPR68; the disease is glioblastoma.